The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse
Little is known about changes within the mitochondrial (mt) genome during tumor progression in general and during initiation and progression of neuroblastoma (NB) in particular. Whole exome sequencing of corresponding healthy tissue, primary tumor and relapsed tumor from 16 patients with NB revealed...
Gespeichert in:
| Veröffentlicht in: | Oncotarget 2016-02, Vol.7 (6), p.6620-6625 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6625 |
|---|---|
| container_issue | 6 |
| container_start_page | 6620 |
| container_title | Oncotarget |
| container_volume | 7 |
| creator | Riehl, Lara M Schulte, Johannes H Mulaw, Medhanie A Dahlhaus, Meike Fischer, Matthias Schramm, Alexander Eggert, Angelika Debatin, Klaus-Michael Beltinger, Christian |
| description | Little is known about changes within the mitochondrial (mt) genome during tumor progression in general and during initiation and progression of neuroblastoma (NB) in particular. Whole exome sequencing of corresponding healthy tissue, primary tumor and relapsed tumor from 16 patients with NB revealed that most NB harbor tumor-specific mitochondrial variants. In relapsed tumors, the status of mt variants changed in parallel to the status of nuclear variants, as shown by increased number and spatio-temporal differences of tumor-specific variants, and by a concomitant decrease of germline variants. As mt variants are present in most NB patients, change during relapse and have a higher copy number compared to nuclear variants, they represent a promising new source of biomarkers for monitoring and phylogenetic analysis of NB. |
| doi_str_mv | 10.18632/oncotarget.6776 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4872737</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1776376055</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-720090fabd3e3a66b475114a3e4761e13c22185ff17bbad0eac5d7efe70935533</originalsourceid><addsrcrecordid>eNpVUU1PwzAMjRAIprE7J5Qjl46kaZP1goQmviQkLts5clN3C2qTkaRI_HvK1wBfbMn2s997hJxxNucLKfJL74xPEDaY5lIpeUAmvCqqLC9LcfinPiGzGJ_ZGGWhFnl1TE5yqUTJVTEh69UWaW-TN1vvmmChoxt0mKyhHbgmGtghtY46HIKvO4jJ90Db4Huaht6HsWeThWS9o8nTgB3sIp6Soxa6iLPvPCXr25vV8j57fLp7WF4_ZqaQMmUqZ6xiLdSNQAFS1oUqOS9AYKEkRy5MnvNF2bZc1TU0DMGUjcIWFavEyExMydUX7m6oe2wMuhSg07tgewhv2oPV_zvObvXGv-pioXIl1Ahw8Q0Q_MuAMeneRoPdyB39EDUfdRVKsvHYlLCvURN8jAHb_RnO9Kch-tcQ_WHIuHL-9739wo_84h04hIw2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776376055</pqid></control><display><type>article</type><title>The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Riehl, Lara M ; Schulte, Johannes H ; Mulaw, Medhanie A ; Dahlhaus, Meike ; Fischer, Matthias ; Schramm, Alexander ; Eggert, Angelika ; Debatin, Klaus-Michael ; Beltinger, Christian</creator><creatorcontrib>Riehl, Lara M ; Schulte, Johannes H ; Mulaw, Medhanie A ; Dahlhaus, Meike ; Fischer, Matthias ; Schramm, Alexander ; Eggert, Angelika ; Debatin, Klaus-Michael ; Beltinger, Christian</creatorcontrib><description>Little is known about changes within the mitochondrial (mt) genome during tumor progression in general and during initiation and progression of neuroblastoma (NB) in particular. Whole exome sequencing of corresponding healthy tissue, primary tumor and relapsed tumor from 16 patients with NB revealed that most NB harbor tumor-specific mitochondrial variants. In relapsed tumors, the status of mt variants changed in parallel to the status of nuclear variants, as shown by increased number and spatio-temporal differences of tumor-specific variants, and by a concomitant decrease of germline variants. As mt variants are present in most NB patients, change during relapse and have a higher copy number compared to nuclear variants, they represent a promising new source of biomarkers for monitoring and phylogenetic analysis of NB.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.6776</identifier><identifier>PMID: 26735174</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Biomarkers, Tumor - genetics ; Cell Transformation, Neoplastic - genetics ; Disease Progression ; High-Throughput Nucleotide Sequencing - methods ; Humans ; Mitochondrial Proteins - genetics ; Mutation - genetics ; Neoplasm Recurrence, Local - genetics ; Neuroblastoma - genetics ; Research Paper</subject><ispartof>Oncotarget, 2016-02, Vol.7 (6), p.6620-6625</ispartof><rights>Copyright: © 2016 Riehl et al. 2016</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-720090fabd3e3a66b475114a3e4761e13c22185ff17bbad0eac5d7efe70935533</citedby><cites>FETCH-LOGICAL-c466t-720090fabd3e3a66b475114a3e4761e13c22185ff17bbad0eac5d7efe70935533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872737/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872737/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26735174$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Riehl, Lara M</creatorcontrib><creatorcontrib>Schulte, Johannes H</creatorcontrib><creatorcontrib>Mulaw, Medhanie A</creatorcontrib><creatorcontrib>Dahlhaus, Meike</creatorcontrib><creatorcontrib>Fischer, Matthias</creatorcontrib><creatorcontrib>Schramm, Alexander</creatorcontrib><creatorcontrib>Eggert, Angelika</creatorcontrib><creatorcontrib>Debatin, Klaus-Michael</creatorcontrib><creatorcontrib>Beltinger, Christian</creatorcontrib><title>The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Little is known about changes within the mitochondrial (mt) genome during tumor progression in general and during initiation and progression of neuroblastoma (NB) in particular. Whole exome sequencing of corresponding healthy tissue, primary tumor and relapsed tumor from 16 patients with NB revealed that most NB harbor tumor-specific mitochondrial variants. In relapsed tumors, the status of mt variants changed in parallel to the status of nuclear variants, as shown by increased number and spatio-temporal differences of tumor-specific variants, and by a concomitant decrease of germline variants. As mt variants are present in most NB patients, change during relapse and have a higher copy number compared to nuclear variants, they represent a promising new source of biomarkers for monitoring and phylogenetic analysis of NB.</description><subject>Biomarkers, Tumor - genetics</subject><subject>Cell Transformation, Neoplastic - genetics</subject><subject>Disease Progression</subject><subject>High-Throughput Nucleotide Sequencing - methods</subject><subject>Humans</subject><subject>Mitochondrial Proteins - genetics</subject><subject>Mutation - genetics</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Neuroblastoma - genetics</subject><subject>Research Paper</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUU1PwzAMjRAIprE7J5Qjl46kaZP1goQmviQkLts5clN3C2qTkaRI_HvK1wBfbMn2s997hJxxNucLKfJL74xPEDaY5lIpeUAmvCqqLC9LcfinPiGzGJ_ZGGWhFnl1TE5yqUTJVTEh69UWaW-TN1vvmmChoxt0mKyhHbgmGtghtY46HIKvO4jJ90Db4Huaht6HsWeThWS9o8nTgB3sIp6Soxa6iLPvPCXr25vV8j57fLp7WF4_ZqaQMmUqZ6xiLdSNQAFS1oUqOS9AYKEkRy5MnvNF2bZc1TU0DMGUjcIWFavEyExMydUX7m6oe2wMuhSg07tgewhv2oPV_zvObvXGv-pioXIl1Ahw8Q0Q_MuAMeneRoPdyB39EDUfdRVKsvHYlLCvURN8jAHb_RnO9Kch-tcQ_WHIuHL-9739wo_84h04hIw2</recordid><startdate>20160209</startdate><enddate>20160209</enddate><creator>Riehl, Lara M</creator><creator>Schulte, Johannes H</creator><creator>Mulaw, Medhanie A</creator><creator>Dahlhaus, Meike</creator><creator>Fischer, Matthias</creator><creator>Schramm, Alexander</creator><creator>Eggert, Angelika</creator><creator>Debatin, Klaus-Michael</creator><creator>Beltinger, Christian</creator><general>Impact Journals LLC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160209</creationdate><title>The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse</title><author>Riehl, Lara M ; Schulte, Johannes H ; Mulaw, Medhanie A ; Dahlhaus, Meike ; Fischer, Matthias ; Schramm, Alexander ; Eggert, Angelika ; Debatin, Klaus-Michael ; Beltinger, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-720090fabd3e3a66b475114a3e4761e13c22185ff17bbad0eac5d7efe70935533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Biomarkers, Tumor - genetics</topic><topic>Cell Transformation, Neoplastic - genetics</topic><topic>Disease Progression</topic><topic>High-Throughput Nucleotide Sequencing - methods</topic><topic>Humans</topic><topic>Mitochondrial Proteins - genetics</topic><topic>Mutation - genetics</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Neuroblastoma - genetics</topic><topic>Research Paper</topic><toplevel>online_resources</toplevel><creatorcontrib>Riehl, Lara M</creatorcontrib><creatorcontrib>Schulte, Johannes H</creatorcontrib><creatorcontrib>Mulaw, Medhanie A</creatorcontrib><creatorcontrib>Dahlhaus, Meike</creatorcontrib><creatorcontrib>Fischer, Matthias</creatorcontrib><creatorcontrib>Schramm, Alexander</creatorcontrib><creatorcontrib>Eggert, Angelika</creatorcontrib><creatorcontrib>Debatin, Klaus-Michael</creatorcontrib><creatorcontrib>Beltinger, Christian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Riehl, Lara M</au><au>Schulte, Johannes H</au><au>Mulaw, Medhanie A</au><au>Dahlhaus, Meike</au><au>Fischer, Matthias</au><au>Schramm, Alexander</au><au>Eggert, Angelika</au><au>Debatin, Klaus-Michael</au><au>Beltinger, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2016-02-09</date><risdate>2016</risdate><volume>7</volume><issue>6</issue><spage>6620</spage><epage>6625</epage><pages>6620-6625</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Little is known about changes within the mitochondrial (mt) genome during tumor progression in general and during initiation and progression of neuroblastoma (NB) in particular. Whole exome sequencing of corresponding healthy tissue, primary tumor and relapsed tumor from 16 patients with NB revealed that most NB harbor tumor-specific mitochondrial variants. In relapsed tumors, the status of mt variants changed in parallel to the status of nuclear variants, as shown by increased number and spatio-temporal differences of tumor-specific variants, and by a concomitant decrease of germline variants. As mt variants are present in most NB patients, change during relapse and have a higher copy number compared to nuclear variants, they represent a promising new source of biomarkers for monitoring and phylogenetic analysis of NB.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>26735174</pmid><doi>10.18632/oncotarget.6776</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1949-2553 |
| ispartof | Oncotarget, 2016-02, Vol.7 (6), p.6620-6625 |
| issn | 1949-2553 1949-2553 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4872737 |
| source | MEDLINE; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free E- Journals |
| subjects | Biomarkers, Tumor - genetics Cell Transformation, Neoplastic - genetics Disease Progression High-Throughput Nucleotide Sequencing - methods Humans Mitochondrial Proteins - genetics Mutation - genetics Neoplasm Recurrence, Local - genetics Neuroblastoma - genetics Research Paper |
| title | The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T22%3A48%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20mitochondrial%20genetic%20landscape%20in%20neuroblastoma%20from%20tumor%20initiation%20to%20relapse&rft.jtitle=Oncotarget&rft.au=Riehl,%20Lara%20M&rft.date=2016-02-09&rft.volume=7&rft.issue=6&rft.spage=6620&rft.epage=6625&rft.pages=6620-6625&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.6776&rft_dat=%3Cproquest_pubme%3E1776376055%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1776376055&rft_id=info:pmid/26735174&rfr_iscdi=true |